Presence of elevated plasma level of PD-L1 has been shown to determine the response of various anti-cancer treatments including surgical reduction, chemotherapy, radiotherapy, anti-EGFR treatment, and anti-PD-1 immunotherapy (131, 207). Here, EGFR is linked to cancer.